India, April 17 -- Shares of uniQure N.V. (QURE) gains 35% on Thursday morning after the company said FDA granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington's disease.
QURE is currently trading at $12.76, up $3.37 or 35.89%, on the Nasdaq. The stock opened its trading at $13.01 after closing Wednesday at $9.39. The stock has traded between $3.73 and $19.18 in the past 52-week period.
The company said the breakthrough therapy designation was based on clinical evidence from phase I/II trials showing meaningful slowing of disease progression.
Additional regulatory update and guidance on the Biologics License Application submission.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-...